Digipath Named Top 10 Cannabis Testing Company in Report by Insight Partners, Market Expected to Reach $2.5 Billion in 2025
LAS VEGAS, Feb. 19, 2019 /PRNewswire/ — Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data and media firm focused on the developing cannabis and hemp markets, is pleased to announce that the Company has been named one of the “Top Leading Market Players” by independent research firm Insight Partners. The report provides key statistics on the Market status of the Cannabis Testing players and offers key trends and opportunities in the market. Moreover, the independent report projects the Cannabis Testing Market to reach $2.5 Billion in 2025 from $1 Billion in 2017. According to Insight, the market is estimated to grow with a compound annual growth rate of 11.9% from 2017-2025.
“We appreciate being recognized as one of the ‘Top Leading Market Players’ and to be listed alongside industry stalwarts such as Agilent, Sciex (Danaher), Merck KGaA and others,” stated Todd Denkin, President and CEO, Digipath, Inc. “We have endeavored for years to earn our place in this growing, competitive field and are proud to have accomplished our goal of becoming a leading brand.”
To review Insight Partner’s press release regarding these statements please follow this link:
About Insight Partners:
Insight Partners is a one stop industry research provider of actionable intelligence. Insight Partners assists clients in getting solutions to their research requirements through their syndicated and consulting research services. They are specialists in Technology, Healthcare, Manufacturing, Automotive and Defense. https://theinsightpartners.com/
About Digipath, Inc. & Digipath Labs, Inc.
Digipath, Inc. supports the cannabis industry’s best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry.
Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization.
Digipath Investor Relations & Financial Media
Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
SOURCE Digipath, Inc.